Open | $1.320 |
Close | $1.310 |
Volume / Avg. | 461.849K / 1.025M |
Day Range | 1.260 - 1.355 |
52 Wk Range | 0.945 - 3.110 |
Market Cap | $121.242M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 50 |
Short Interest | 2.84% |
Days to Cover | 4 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Immunic (NASDAQ: IMUX) through any online brokerage.
Other companies in Immunic’s space includes: Molecular Partners (NASDAQ:MOLN), Vincerx Pharma (NASDAQ:VINC), Outlook Therapeutics (NASDAQ:OTLK), Anixa Biosciences (NASDAQ:ANIX) and Galectin Therapeutics (NASDAQ:GALT).
The latest price target for Immunic (NASDAQ: IMUX) was reported by Wedbush on Tuesday, October 10, 2023. The analyst firm set a price target for 7.00 expecting IMUX to rise to within 12 months (a possible 419.21% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Immunic (NASDAQ: IMUX) is $1.3482 last updated March 18, 2024 at 4:01 PM EDT.
There are no upcoming dividends for Immunic.
Immunic’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Immunic.
Immunic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.